Inspire Medical Systems Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Tim Herbert

Directeur général

US$7.5m

Rémunération totale

Pourcentage du salaire du PDG	9.2%
Durée du mandat du directeur général	17yrs
Propriété du PDG	1.0%
Durée moyenne d'occupation des postes de direction	4.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Tim Herbert a-t-elle évolué par rapport aux bénéfices de Inspire Medical Systems?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$33m
Jun 30 2024	n/a	n/a	US$6m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$7m	US$690k	-US$21m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$41m
Mar 31 2023	n/a	n/a	-US$44m
Dec 31 2022	US$6m	US$645k	-US$45m
Sep 30 2022	n/a	n/a	-US$50m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$43m
Dec 31 2021	US$1m	US$620k	-US$42m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$57m
Dec 31 2020	US$5m	US$506k	-US$57m
Sep 30 2020	n/a	n/a	-US$59m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$3m	US$440k	-US$33m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$3m	US$418k	-US$22m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$21m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$600k	US$380k	-US$18m

Rémunération vs marché: La rémunération totale de Tim ($USD 7.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 3.50M ).

Rémunération et revenus: La rémunération de Tim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Tim Herbert (61 yo)

17yrs

Titularisation

US$7,490,775

Compensation

Mr. Timothy P. Herbert, also known as Tim, has been Chief Executive Officer, President and Director of Inspire Medical Systems, Inc. since November 2007 and has been its Chairman since May 2, 2024. He is t...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Timothy Herbert	Founder	17yrs	US$7.49m	0.99% € 48.4m
Richard Buchholz	Chief Financial Officer	10.5yrs	US$2.30m	0.10% € 5.0m
Randall Ban	Chief Commercial Officer	5.8yrs	US$2.26m	0.0023% € 114.1k
Charisse Sparks	Chief Medical Officer	1.3yrs	US$211.35k	0.0031% € 153.4k
Carlton Weatherby	Chief Strategy Officer	1.3yrs	US$2.10m	0% € 0
John Rondoni	Chief Technology Officer	2.5yrs	US$2.10m	0.029% € 1.4m
Ezgi Yagci	Vice President of Investor Relations	no data	pas de données	pas de données
Bryan Phillips	Senior VP	3.8yrs	US$2.69m	0.0044% € 214.3k
Melissa Mann	Chief People Officer	less than a year	pas de données	pas de données
Ivan Lubogo	Senior Vice President of U.S. Sales	4.8yrs	pas de données	pas de données
Andreas Henke	Executive VP & MD of Europe	4.8yrs	pas de données	pas de données
Megan Rowekamp	Director of Financial Reporting	no data	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2DR est considérée comme expérimentée (ancienneté moyenne 4.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Timothy Herbert	Founder	17yrs	US$7.49m	0.99% € 48.4m
Casey Tansey	Independent Director	16.8yrs	US$235.88k	0.068% € 3.4m
Dana Mead	Independent Director	16.3yrs	US$238.38k	0.069% € 3.4m
Shawn McCormick	Independent Director	7.8yrs	US$248.38k	0.085% € 4.2m
Shelley Broader	Independent Director	4.1yrs	US$243.38k	0.0060% € 292.5k
Gary Ellis	Lead Independent Director	5.3yrs	US$243.38k	0.012% € 586.0k
Georgia Garinois-Melenikiotou	Independent Director	4.3yrs	US$238.38k	0.0050% € 245.8k
Myriam J. McAdams	Independent Director	less than a year	US$271.56k	0% € 0
Cynthia Burks	Independent Director	2.3yrs	US$235.88k	0.0022% € 109.6k

5.3yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2DR sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

Inspire Medical Systems Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Inspire Medical Systems, Inc. Announces Appointment of Melissa J. Mann as Chief People Officer

Inspire Medical Systems, Inc. Announces Board Retirements

Inspire Medical Systems, Inc., Annual General Meeting, May 02, 2024

Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. from Its Board of Directors, Effective on May 2, 2024

Inspire Medical Systems, Inc. Announces Appointment of Myriam J. Curet as Independent Director

Insufficient new directors

Recent updates

New minor risk - Shareholder dilution

Inspire Medical Systems, Inc. Raises Earnings Guidance for the Year 2024

Inspire Medical Systems, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Inspire Medical Systems, Inc. (NYSE:INSP) announces an Equity Buyback for $150 million worth of its shares.

Inspire Medical Systems, Inc. (NYSE:INSP) announces an Equity Buyback for $150 million worth of its shares.

Second quarter 2024 earnings released: EPS: US$0.33 (vs US$0.41 loss in 2Q 2023)

Inspire Medical Systems, Inc. Announces FD Approval of the Inspire V System

Forecast to breakeven in 2024

Inspire Medical Systems, Inc. Revises Earnings Guidance for the Year 2024

Inspire Medical Systems, Inc. Announces Appointment of Melissa J. Mann as Chief People Officer

Inspire Medical Systems, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Forecast breakeven date moved forward to 2024

Now 38% undervalued after recent price drop

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.53 loss in 1Q 2023)

Inspire Medical Systems, Inc. Revises Financial Guidance for the Full Year 2024

Now 21% undervalued

Inspire Medical Systems, Inc. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.72 loss per share (vs US$1.60 loss in FY 2022)

Inspire Medical Systems, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Inspire Medical Systems, Inc. Announces Board Retirements

Inspire Medical Systems, Inc., Annual General Meeting, May 02, 2024

Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. from Its Board of Directors, Effective on May 2, 2024

Inspire Medical Systems, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Forecast to breakeven in 2025

Inspire Medical Systems, Inc. to Report Fiscal Year 2023 Results on Jan 08, 2024

Inspire Medical Systems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024

Inspire Medical Systems, Inc. Announces Appointment of Myriam J. Curet as Independent Director

Gainey McKenna & Egleston Announces A Class Action Lawsuit Filed Against Inspire Medical Systems Inc

New minor risk - Shareholder dilution

Inspire Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.60 loss in 3Q 2022)

Now 22% undervalued after recent price drop

Insufficient new directors

New minor risk - Share price stability

Now 29% undervalued after recent price drop

Inspire Medical Systems, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings released: US$0.41 loss per share (vs US$0.53 loss in 2Q 2022)

Inspire Medical Systems, Inc. Announces the Addition of Charisse Y. Sparks, M.D., as Chief Medical Officer

Inspire Medical Systems, Inc. Appoints Carlton Weatherby as Chief Strategy Officer

Inspire Medical Systems, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Inspire Medical Systems, Inc.(NYSE:INSP) dropped from Russell 2000 Dynamic Index

First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.61 loss in 1Q 2022)

Full year 2022 earnings released: US$1.60 loss per share (vs US$1.54 loss in FY 2021)

Forecast to breakeven in 2025

Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

Inspire Medical Systems, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Inspire Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 07, 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.38 loss in 3Q 2021)

Inspire Medical Systems, Inc. Updates Revenue Guidance for the Full Year of 2022

Inspire Medical Systems, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Inspire Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of $215 million.

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.48 loss in 2Q 2021)

Inspire Medical Systems, Inc. Revises Earnings Guidance for Full Year 2022

Inspire Medical Systems, Inc. Announces Appointment of Two New Independent Directors to Its Board

Inspire Medical Systems, Inc. Announces United States Food and Drug Administration Approval of Expanded, Full-Body MRI Compatibility with Inspire Therapy

Inspire Medical Systems, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.60 loss in 1Q 2021)

Inspire Medical Systems, Inc. Revises Revenue Guidance for the Year 2022

Inspire Medical Systems, Inc. to Report Q1, 2022 Results on May 03, 2022

Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.38 loss per share (vs US$0.39 loss in 3Q 2020)

Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2021

Second quarter 2021 earnings released: US$0.48 loss per share (vs US$0.88 loss in 2Q 2020)

Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.67 loss in 1Q 2020)

Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2021

Inspire Medical Systems, Inc., Annual General Meeting, Apr 29, 2021